Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy
Citations Over TimeTop 20% of 1999 papers
Abstract
The synthesis and evaluation of analogues of previously reported farnesyltransferase inhibitors, pyridyl benzyl ether 3 and pyridylbenzylamine 4, are described. Substitution of 3 at the 5-position of the core aryl ring resulted in inhibitors of equal or less potency against the enzyme and decreased efficacy in a cellular assay against Ras processing by the enzyme. Substitution of 4 at the benzyl nitrogen yielded 26, which showed improved efficacy and potency and yet presented a poor pharmacokinetic profile. Further modification afforded 30, which demonstrated a dramatically improved pharmacokinetic profile. Compounds 26 and 29 demonstrated significant in vivo efficacy in nude mice inoculated with MiaPaCa-2, a human pancreatic tumor-derived cell line.
Related Papers
- → New farnesyltransferase inhibitors in the phenothiazine series(2012)38 cited
- → J-104,871, a Novel Farnesyltransferase Inhibitor, Blocks Ras Farnesylation In Vivo in a Farnesyl Pyrophosphate-Competitive Manner(1998)37 cited
- → Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors(2005)22 cited
- → Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors(1997)14 cited
- → Synthesis and Evaluation of Some Hydroxyproline-Derived Peptidomimetics as Isoprenyltransferase Inhibitors.(2000)2 cited